CGRP antagonists
    2.
    发明授权
    CGRP antagonists 有权
    CGRP拮抗剂

    公开(公告)号:US07834007B2

    公开(公告)日:2010-11-16

    申请号:US11508568

    申请日:2006-08-23

    摘要: The present invention encompasses compounds of Formula I which are antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.

    摘要翻译: 本发明包括作为降钙素基因相关肽受体(“CGRP受体”)的拮抗剂的式I化合物,包含它们的药物组合物,鉴定它们的方法,使用它们的治疗方法及其在治疗神经源性治疗中的用途 血管舒张,神经源性炎症,偏头痛和其他头痛,热损伤,循环休克,与更年期相关的潮红,气道炎症性疾病如哮喘和慢性阻塞性肺病(COPD)以及治疗可通过拮抗作用的其他病症 的CGRP受体。

    Constrained compounds as CGRP-receptor antagonists
    6.
    发明授权
    Constrained compounds as CGRP-receptor antagonists 有权
    约束化合物作为CGRP受体拮抗剂

    公开(公告)号:US07384931B2

    公开(公告)日:2008-06-10

    申请号:US11417326

    申请日:2006-05-03

    CPC分类号: C07D471/04 C07D487/04

    摘要: The invention encompasses constrained bicyclic and tricyclic CGRP-receptor antagonists, methods for identifying them, pharmaceutical compositions comprising them, and methods for their use in therapy for treatment of migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors

    摘要翻译: 本发明包括受限制的双环和三环CGRP受体拮抗剂,鉴定它们的方法,包含它们的药物组合物及其用于治疗偏头痛和其他头痛,神经源性血管舒张,神经源性炎症,热损伤,循环休克,冲洗的方法 与更年期,气道炎症性疾病如哮喘和慢性阻塞性肺疾病(COPD)有关的其他病症,其治疗可以通过CGRP受体的拮抗作用

    CGRP receptor antagonist
    10.
    发明授权
    CGRP receptor antagonist 有权
    CGRP受体拮抗剂

    公开(公告)号:US08481546B2

    公开(公告)日:2013-07-09

    申请号:US13038550

    申请日:2011-03-02

    IPC分类号: C07D401/14 A61K31/496

    CPC分类号: C07D401/14 C07K5/0806

    摘要: The disclosure generally relates to the compound of formula I, (R)—N-(3-(7-methyl-1H-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)piperazin-1-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide, including pharmaceutically acceptable salts, which is a CGRP-receptor antagonist. The disclosure also relates to pharmaceutical compositions and methods for using the compound in the treatment of CGRP related disorders including migraine headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and cancer.

    摘要翻译: 本发明一般涉及式I化合物,(R)-N-(3-(7-甲基-1H-吲唑-5-基)-1-(4-(1-甲基哌啶-4-基)哌嗪-1-基) 哌啶-1-基)-1-氧代丙-2-基)-4-(2-氧代-1,2-二氢喹啉-3-基)哌啶-1-甲酰胺,包括药学上可接受的盐,其是CGRP-受体拮抗剂。 本公开还涉及用于治疗CGRP相关疾病的药物组合物和方法,包括偏头痛,神经源性血管舒张,神经源性炎症,热损伤,循环休克,与绝经相关的潮红,气道炎症性疾病如哮喘,慢性阻塞性 肺部疾病(COPD)和癌症。